PubMed Health⌕ Search

PubMed · 17222380

Recent progress in the determination of solid surface tensions from contact angles.

Abstract

Advancing contact angles of different liquids measured on the same solid surface fall very close to a smooth curve when plotted as a function of liquid surface tension, i.e., gamma(lv)costheta versus gamma(lv). Changing the solid surface, and hence gamma(sv), shifts the curve in a regular manner. These patterns suggest that gamma(lv)costheta depends only on gamma(lv) and gamma(sv). Thus, an "equation of state for the interfacial tensions" was developed to facilitate the determination of solid surface tensions from contact angles in conjunction with Young's equation. However, a close examination of the smooth curves showed that contact angles typically show a scatter of 1-3 degrees around the curves. The existence of the deviations introduces an element of uncertainty in the determination of solid surface tensions. Establishing that (i) contact angles are exclusively a material property of the coating polymer and do not depend on experimental procedures and that (ii) contact angle measurements with a sophisticated methodology, axisymmetric drop shape analysis (ADSA), are highly reproducible guarantees that the deviations are not experimental errors and must have physical causes. The contact angles of a large number of liquids on the films of four different fluoropolymers were studied to identify the causes of the deviations. Specific molecular interactions at solid-vapor and/or solid-liquid interfaces account for the minor contact angle deviations. Such interactions take place in different ways. Adsorption of vapor of the test liquid onto the solid surface is apparently the only process that influences the solid-vapor interfacial tension (gamma(sv)). The molecular interactions taking place at the solid-liquid interface are more diverse and complicated. Parallel alignment of liquid molecules at the solid surface, reorganization of liquid molecules at the solid-liquid interface, change in the configuration of polymer chains due to contact with certain probe liquids, and intermolecular interactions between solid and liquid molecules cause the solid-liquid interfacial (gamma(sl)) tension to be different from that predicted by the equation of state, i.e., gamma(sl) is not a precise function of gamma(lv) and gamma(sv). In other words, the experimental contact angles deviate from the "ideal" contact angle pattern. Specific criteria are proposed to identify probe liquids which eliminate specific molecular interactions. Octamethylcyclotetrasiloxane (OMCTS) and decamethylcyclopentasiloxane (DMCPS) are shown to meet those criteria, and therefore are the most suitable liquids to characterize surface tensions of low energy fluoropolymer films with an accuracy of +/-0.2 mJ/m2.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Tavana, A W Neumann. 2007-01-11. Recent progress in the determination of solid surface tensions from contact angles.. https://doi.org/10.1016/j.cis.2006.11.024

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗